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Available online 12 October 2017X-linked adrenoleukodystrophy (X-ALD) is an inherited disorder caused by a mutation in the ATP-binding cas-
sette transporter subfamily D member 1 (ABCD1) gene. We generated two induced pluripotent stem cell
(iPSC) lines from X-ALD patients with adrenomyeloneuropathy (AMN) by Sendai virus containing OCT4, SOX2,
KLF4 and c-MYC. Established iPSC lines expressed various pluripotency markers, had differentiation potential
of three germ layers in vitro, had normal karyotype and retained ABCD1 mutation.
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These iPSC lines (YUSEVi005-A and YUSEVi006-A) will be useful for
modeling X-ALD disease and developing drugs to treat this disease.
Resource details
X-linked adrenoleukodystrophy (X-ALD) is an inherited disorder
caused by ATP-binding cassette transporter subfamily D member 1
(ABCD1) gene mutation (Mosser et al., 1993). Two human ﬁbroblast
cells from X-ALD patients with ABCD1 mutation were reprogrammed
into iPSCs by Sendai virus containing OCT4, SOX2, KLF4, and c-MYC
(Fig. 1A, Table 1). The established iPSC lines (YUSEVi005-A and
YUSEVi006-A) expressed various pluripotency markers including
OCT4, NANOG, and TRA-1-81 (Fig. 1B–C). One patient harboured one al-
lele transition (G N A) of ABCD1 gene, which substituted Serine for Gly-
cine at codon 512, as veriﬁed by genomic DNA sequencing of ABCD1 in
YUSEVi005-A. The other patient harboured a deletion of three nucleo-
tides of ABCD1 gene at codon 657 as veriﬁed by genomic DNA sequenc-
ing of ABCD1 in YUSEVi006-A (Fig. 1D). YUSEVi005-A and YUSEVi006-A
could differentiate into cells of the three embryonic germ layers in vitro
(Fig. 1E), had a normal karyotype without abnormalities in the number
or structure of chromosomes (Fig. 1F), and were negative forMycoplas-
ma contamination (Fig. 1G). STR analysis showed that parentalecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Characterization of iPSC lines (YUSEVi005-A and YUSEVi006-A).
47D. Son et al. / Stem Cell Research 25 (2017) 46–49ﬁbroblasts and the newly created YUSEVi005-A and YUSEVi006-A iPSC
lines shared alleles with 100% match (Supplementary data, Table 2).Materials and methods
Cell culture
Human ﬁbroblasts were isolated from patients carrying a ABCD1
mutation and cultured in growth media (GM; DMEM supplemented
with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, 2 nM L-
glutamine) at 37 °C in 5% CO2.Generation of iPSC from X-ALD patient ﬁbroblasts
X-ALD patient ﬁbroblasts were reprogrammed to iPSC using
CytoTune™-iPS 2.0 Sendai Reprogramming Kit (Invitrogen) according
to the manufacturer's instructions. After transduction, cells were
reseeded on mouse embryonic ﬁbroblast (STO) feeder cells (ATCCTable 1
Summary of lines
iPSC line names Abbreviation in ﬁgures Gender A
YUSEVi005-A AMN 5 Male 3
YUSEVi006-A AMN 6 Male 4CRL-1503) and cultured in conventional human embryonic stem cell
medium (Jang et al., 2011) for 30 days.
Immunocytochemistry
The iPSC lines (YUSEVi005-A and YUSEVi006-A) were ﬁxed in 4%
paraformaldehyde, incubated with primary antibodies overnight at 4
°C, and then incubated with secondary antibodies for 1 h at room tem-
perature. Nuclei were stainedwith DAPI for 5min at room temperature.
Immunoﬂuorescence was visualized under ﬂuorescence microscope
(Olympus IX71) (Table 3).
Flow cytometry analysis
The iPSC lines (YUSEVi005-A and YUSEVi006-A) were dissociated
with accutase, blocked with 10% FBS for 30 min at 4 °C, incubated
with a primary antibody for 1 h at 4 °C and then incubated with a sec-
ondary antibody for 1 h at 4 °C. Expression of surface marker of
pluripotency was analysed by FACSVerse ﬂow cytometer (BDge Ethnicity Genotype of locus Disease
4 Korean p.Gly512Ser
(c.1534G N A)
X-ALD
3 Korean p.Ile657del
(c.1968_1970delCAT)
X-ALD
Table 2
Characterization and validation.
Classiﬁcation Test Result Data
Morphology Photography Visual record of the line: normal Fig. 1 panel A
Phenotype Immunocytochemistry Assess staining/expression of pluripotency markers:
OCT4, NANOG, TRA-1-81
Fig. 1 panel B
Flow cytometry Assess antigen levels & cell surface markers:
TRA-1-81: 98.3% (YUSEVi005-A)
TRA-1-81: 95.2% (YUSEVi006-A)
Fig. 1 panel C
Genotype Karyotype (G-banding) and resolution 46 XY, Resolution 450 (YUSEVi005-A)
46 XY, Resolution 475 (YUSEVi006-A)
Fig. 1 panel F
Identity Microsatellite PCR (mPCR) N/A
STR analysis 18 locus tested. 100% match Submitted in archive with journal
Mutation analysis (IF APPLICABLE) Sequencing Hemizygote mutation Fig. 1 panel D
Southern Blot OR WGS N/A
Microbiology and virology Mycoplasma Mycoplasma testing by luminescence. Negative Fig. 1 panel G
Differentiation potential In vitro differentiation NESTIN, Brachyury (T), and α-feto protein Fig. 1 panel E
Donor screening (OPTIONAL) HIV 1 + 2 Hepatitis B, Hepatitis C N/A
Genotype additional info (OPTIONAL) Blood group genotyping N/A
HLA tissue typing N/A
48 D. Son et al. / Stem Cell Research 25 (2017) 46–49Biosciences). Negative samples were only labelled with the secondary
antibody (Table 3).In vitro differentiation
The iPSC lines (YUSEVi005-A and YUSEVi006-A) were cultured in
chemically deﬁned reprogrammingmedium (Chen et al., 2011)without
basic ﬁbroblast growth factor and transforming growth factor β for
3 days and then in the speciﬁed differentiation medium for 10 days.
For ectodermal differentiation, cells were cultured in DMEM/F12
(Lonza) supplemented with 1× N2 (Thermo Fisher Scientiﬁc), 1× B27
(Thermo Fisher Scientiﬁc), 10 ng/ml of leukemia inhibitory factor
(Millipore), 2 μM SB431542 and 3 μM CHIR99021. For mesodermal dif-
ferentiation, cells were cultured in Advanced-RPMI (Thermo Fisher Sci-
entiﬁc) supplemented with 8 μM CHIR99021. For endodermal
differentiation, cells were cultured in DMEM-low glucose (Hyclone)
supplemented with 10% FBS (Hyclone). The in vitro differentiation po-
tential of the iPSC lines was conﬁrmed by immunocytochemistry
(Table 3).Table 3
Reagents details.
Antibodies used for immunocytochemistry/ﬂow-cytometry
Antibody
Pluripotency markers Rabbit anti-OCT4
Pluripotency markers Goat anti-NANOG
Pluripotency markers Mouse anti-TRA-1-81
Differentiation markers Mouse anti-NESTIN
Differentiation markers Rabbit anti-Brachyury
Differentiation Markers Goat anti-AFP
Secondary antibodies Alexa Fluor 488-conjugated Donkey Anti-Mouse IgM
Secondary antibodies Cy3-conjugated Donkey Anti-Mouse IgG
Secondary antibodies Cy3-conjugated Donkey Anti-Goat IgG
Secondary antibodies Cy3-conjugated Donkey Anti-Rabbit IgG
Primers
Target
Targeted mutation analysis/sequencing
(YUSEVi005-A)
ABCD1(742 bp; NG_009022.2: 1992
Targeted mutation analysis/sequencing
(YUSEVi006-A)
ABCD1(NG_009022.2: 20649 to 239
Targeted mutation analysis/sequencing
(YUSEVi006-A)
ABCD1(NG_009022.2: 23245 to 236Sequencing analysis of the ABCD1 mutant alleles and karyotyping
Genomic DNAwas isolated from the iPSC lines using aWizard® Ge-
nomic DNA Puriﬁcation Kit (Promega). Mutation sequencing of AMN5
and AMN6 were performed using AMN5 and AMN6-speciﬁc primers
(Table 3). Karyotyping was performed by GTG banding by Samkwang
Medical Laboratories.Mycoplasma contamination detection
The absence of mycoplasma contamination was conﬁrmed using
MycoAlert™ PLUS Mycoplasma Detection kit (Lonza).STR analysis
Parentﬁbroblasts and their established iPSC lines (YUSEVi005-A and
YUSEVi006-A) were authenticated using STR analysis by Cosmo
Genetech.Dilution Company Cat# and RRID
1:200 Millipore Cat# AB3209, RRID: AB_2167706
1:200 R and D Systems Cat# AF1997, RRID:AB_355097
1:200 Millipore Cat# MAB4381, RRID:AB_177638
1:200 Millipore Cat# MAB5326, RRID:AB_2251134
1:200 Abcam Cat# ab20680, RRID:AB_727024
1:50 Santa Cruz Biotechnology Cat# sc-8108, RRID:AB_633815
1:500 Thermo Fisher Scientiﬁc Cat# A-21042, RRID:AB_2535711
1:500 Jackson ImmunoResearch Labs Cat# 715-165-151, RRID:AB_2315777
1:500 Jackson ImmunoResearch Labs Cat# 705–165-147, RRID: AB_2307351
1:500 Jackson ImmunoResearch Labs Cat# 711-165-152, RRID:AB_2307443
Forward/Reverse primer (5′-3′)
1 to 20662) CTGTGGCAGAATAGGCCCTT/CTCCCCCAAGATACTCTGCG
32; 3284 bp) GTATCTTGGGGGAGGCAGAG/GGTGCTGCTGTCTCCTTCAT
15; 371 bp) AAGGGGAAGTAGCAGCTGTG/AGGAGAGGGACAGGGTCAG
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Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.scr.2017.10.003.References
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